Briumvi®
Briumvi® is a monoclonal antibody that binds to a molecule (CD20) on the surface of immune cells called B cells and removes them from circulating blood. Briumvi® is approved by the FDA for the treatment of relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
WHAT IT TREATS: |
MANUFACTURER: TG Therapeutics, Inc. |
CLASS: Monoclonal Antibodies |
PRESCRIBED BY: Neurologists |
HOW ADMINISTERED: IV Infusion |
FREQUENCY: Second infusion two weeks after first infusion |
Length of infusion: First infusion about four hours. Subsequent infusions about one hour. |
FOR MORE INFORMATION: |
